Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 61Neoplasm Metastasis 10Stomach Neoplasms 9Brain Neoplasms 6Neoplasms 4HER2-positive Breast Cancer 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Lung Neoplasms 3Inflammatory Breast Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Meningeal Carcinomatosis 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Sarcoma 1Recurrence 1Pathologic Processes 1Ovarian Neoplasms 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Trastuzumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡